Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: Phase 1b, Randomized, Double-Blind, Multiple-Dose Ranging Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Antiviral Activity of GS-5816 in Subjects With Chronic Hepatitis C Virus Infection
Brief Summary: The primary objective of the study is to evaluate the safety, tolerability, and antiviral activity of velpatasvir (formerly GS-5816) in HCV treatment naive participants with genotypes 1-6.


Options:
A: Arm Label: GSK2336805; Type: EXPERIMENTAL; Interventions: Drug: GSK2336805 | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: GSK2336805 Matching Placebo | Arm Label: GSK2336805 + pegylated interferon alfa-2a + ribavrin; Type: EXPERIMENTAL; Interventions: Drug: GSK2336805, Drug: Pegylated interferon alfa-2a, Drug: Ribavirin | Arm Label: Placebo + pegylated interferon alfa-2a + ribavirin; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegylated interferon alfa-2a, Drug: Ribavirin, Drug: GSK2336805 Matching Placebo | Intervention Type: DRUG; Name: GSK2336805; Assigned to Arm(s): GSK2336805, GSK2336805 + pegylated interferon alfa-2a + ribavrin | Intervention Type: DRUG; Name: Pegylated interferon alfa-2a; Assigned to Arm(s): GSK2336805 + pegylated interferon alfa-2a + ribavrin, Placebo + pegylated interferon alfa-2a + ribavirin | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): GSK2336805 + pegylated interferon alfa-2a + ribavrin, Placebo + pegylated interferon alfa-2a + ribavirin | Intervention Type: DRUG; Name: GSK2336805 Matching Placebo; Assigned to Arm(s): Placebo, Placebo + pegylated interferon alfa-2a + ribavirin
B: Arm Label: Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Daclatasvir, Peginterferon alpha-2a, ribavirin (B); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Daclatasvir, Peginterferon alpha-2a, ribavirin (C); Type: EXPERIMENTAL; Interventions: Drug: Daclatasvir, Drug: Peginterferon alpha-2a, Drug: ribavirin | Arm Label: Placebo, Peginterferon alpha-2a, ribavirin (D); Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: Peginterferon alpha-2a, Drug: ribavirin | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A) | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B) | Intervention Type: DRUG; Name: Daclatasvir; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (C) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo, Peginterferon alpha-2a, ribavirin (D) | Intervention Type: DRUG; Name: Peginterferon alpha-2a; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B), Daclatasvir, Peginterferon alpha-2a, ribavirin (C), Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A), Placebo, Peginterferon alpha-2a, ribavirin (D) | Intervention Type: DRUG; Name: ribavirin; Assigned to Arm(s): Daclatasvir, Peginterferon alpha-2a, ribavirin (B), Daclatasvir, Peginterferon alpha-2a, ribavirin (C), Daclatasvir, plus Peginterferon alpha-2a, ribavirin (A), Placebo, Peginterferon alpha-2a, ribavirin (D)
C: Arm Label: Velpatasvir 5 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 25 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 50 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 100 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 1a); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 1b); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 2); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 25 mg (GT 3); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 50 mg (GT 3); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 3); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir 150 mg (GT 4); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Arm Label: Velpatasvir up to 400 mg (GT 2); Type: EXPERIMENTAL; Interventions: Drug: Velpatasvir, Drug: Placebo | Intervention Type: DRUG; Name: Velpatasvir; Assigned to Arm(s): Velpatasvir 100 mg (GT 1a), Velpatasvir 150 mg (GT 1a), Velpatasvir 150 mg (GT 1b), Velpatasvir 150 mg (GT 2), Velpatasvir 150 mg (GT 3), Velpatasvir 150 mg (GT 4), Velpatasvir 25 mg (GT 1a), Velpatasvir 25 mg (GT 3), Velpatasvir 5 mg (GT 1a), Velpatasvir 50 mg (GT 1a), Velpatasvir 50 mg (GT 3), Velpatasvir up to 400 mg (GT 2) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Velpatasvir 100 mg (GT 1a), Velpatasvir 150 mg (GT 1a), Velpatasvir 150 mg (GT 1b), Velpatasvir 150 mg (GT 2), Velpatasvir 150 mg (GT 3), Velpatasvir 150 mg (GT 4), Velpatasvir 25 mg (GT 1a), Velpatasvir 25 mg (GT 3), Velpatasvir 5 mg (GT 1a), Velpatasvir 50 mg (GT 1a), Velpatasvir 50 mg (GT 3), Velpatasvir up to 400 mg (GT 2)
D: Arm Label: Standard; Type: ACTIVE_COMPARATOR; Interventions: Drug: Pegylated Interferon alfa-2b, Drug: Ribavirin, Drug: Sofosbuvir | Arm Label: Simeprevir + Sofosbuvir; Type: EXPERIMENTAL; Interventions: Drug: Simeprevir, Drug: Sofosbuvir | Intervention Type: DRUG; Name: Pegylated Interferon alfa-2b; Assigned to Arm(s): Standard | Intervention Type: DRUG; Name: Simeprevir; Assigned to Arm(s): Simeprevir + Sofosbuvir | Intervention Type: DRUG; Name: Ribavirin; Assigned to Arm(s): Standard | Intervention Type: DRUG; Name: Sofosbuvir; Assigned to Arm(s): Simeprevir + Sofosbuvir, Standard

Answer: C